Definition
The type of test used to determine the results of human epidermal growth factor receptor-2 (HER2) at the time of diagnosis of the primary tumour, as represented by a code.
Components
Data Element (this item)
-
Data Element ConceptPerson with cancer—human epidermal growth factor receptor-2 test type
-
Object ClassPerson with cancer
-
PropertyHuman epidermal growth factor receptor-2 test type
-
-
Value DomainHER2 test type code N
Representation
This representation is based on the value domain for this data element, more information is available at " HER2 test type code N ".| Data Type | Number |
|---|---|
| Format | N |
| Maximum character length | 1 |
| Value | Meaning | Start Date | End Date | |
|---|---|---|---|---|
| Permissible Values | 1 | Fluorescence in situ hybridisation (FISH) | ||
| 2 | Brightfield in situ hybridisation | |||
| 3 | Immunochemistry (IHC) | |||
| 8 | Other | |||
| Supplementary Values | 9 | Test type not stated or unknown |
Comments
Guide for use:
Record the test type corresponding to the test result recorded in 'Person with Cancer - human epidermal growth factor receptor-2 test result'.
Origin:
National Breast and Ovarian Cancer Centre (NBOCC)
Australasian Association of Cancer Registries (AACR)
Australian Institute of Health and Welfare (AIHW)
Comments:
Immunochemistry (IHC) measures how much HER2 protein is present in the tumour sample. Fluorescence in situ hybridisation (FISH), chromogenic in situ hybridisation (CISH) and silver in situ hybridisation (SISH) measure the amount of amplification of the gene responsible for HER2. The type of HER2 test used to determine HER2 status affects the accuracy of the information.